FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580025711> ?p ?o ?g. }

• W2580025711 abstract "Abstract Abstract 2265 Poster Board II-242 While reduced intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT) regimens have expanded the scope of transplantation, use of these regimens are associated with a higher relapse rate. Disease relapse following following allo-HSCT in acute myeloid leukemia(AML) and high-risk myelodysplastic syndromes(MDS) is associated with a particularly poor prognosis. We performed a retrospective analysis on 157 consecutive patients with high risk (AML/MDS) who received a uniform fludarabine-busulphan based RIC HSCT at our centre between Jul 2002 and Oct 2006 and identified 45(28%) patients who had subsequent cytogenetic or morphological relapse. We proceeded to analyse the patient/disease characteristics of the 45 patients to predict response to salvage therapy. The patient diagnoses were: 19 MDS RAEB I/II, 17 AML, 6 CMML, 3 CML-blast crisis. All patients had received intensive chemotherapy prior to transplantation (median 2 courses, range 1-6). 7 patients were receiving a second allo-HSCT. At time of transplantation, 34 patients had <5% bone marrow blasts, with 11(24.4%) having >5% blasts. 81% of patients had intermediate/poor risk cytogenetics. The median patient age at time of relapse was 52yrs (range:24-72). The median time to relapse was 246 days(range:34-1034). The median survival following relapse was 203 days, with a 2-year OS from time of relapse of 24%+/-6%. On univariate analysis, the time to relapse post-HSCT was the most significant predictive factor of OS post-relapse. All patients who had relapsed <180 days post-HSCT (n=22) died of disease progression within 6 months of relapse. 2-yr OS post-relapse for patients who had relapsed >180 post-HSCT was 43%+/-10% (p<0.01). There was no significant difference in disease type, stage at transplant, cytogenetics between early and late relapsing patients. In addition, patients with >5% blasts at time of allograft had an inferior post-relapse 2-yrs OS when compared with those in remission (9% vs 29%, p=0.1). Patients were further analysed based on the salvage treatment received; no therapy: 5, donor lymphocyte infusions(DLI) only:6, chemotherapy only:12, intensive chemotherapy (defined as a regimen containing high dose arabinose cytarabine) followed by DLI:17, second allograft:5. There was a significant difference in therapy given dependant on the time-post relapse, with 18/22 patients who had early relapse receiving either no therapy, or DLI/chemotherapy alone, while 18/23 late relapsing patients received intensive chemotherapy+DLI or a 2nd allograft. At one year post-relapse, only 1 patient who received DLI only (out of those who received no therapy/DLI only/chemotherapy only) was alive. In contrast, 10/22 patients who received either intensive chemotherapy+DLI or a 2nd allograft were alive and in durable remission with a median survival post-relapse of 1767 days (range:1123-2581), with no significant difference in outcomes between either form of therapy (2 year post-relapse OS: chemo/DLI 47% vs 2nd allograft 40%). In conclusion, the disease kinetics and time to relapse following RIC HSCT play a significant role in determining subsequent outcomes. The prognosis of patients who relapse within 6 months remains extremely poor. In contrast, we demonstrate that of patients who relapse after 6 months, treatment with chemotherapy followed by cellular therapy (either in the form of intensive chemotherapy followed by DLI, or a 2nd RIC followed by HSCT), can effectively salvage a significant proportion of patients with attainment of durable long-term remissions. Disclosures: Off Label Use: fludarabine, alemtuzumab- used off-label for transplant conditioning. Marsh:Genzyme: Consultancy, Honoraria." @default.
• W2580025711 created "2017-02-03" @default.
• W2580025711 creator A5001573915 @default.
• W2580025711 creator A5011143459 @default.
• W2580025711 creator A5026724408 @default.
• W2580025711 creator A5032585809 @default.
• W2580025711 creator A5045018770 @default.
• W2580025711 creator A5051478948 @default.
• W2580025711 creator A5055334016 @default.
• W2580025711 creator A5072940837 @default.
• W2580025711 creator A5080466962 @default.
• W2580025711 creator A5081252933 @default.
• W2580025711 date "2009-11-20" @default.
• W2580025711 modified "2023-09-27" @default.
• W2580025711 title "Late Relapses Following Reduced Intensity Conditioning Allogeneic Haematopoietic Stem Cell Transplantation for Myeloid Malignancies Can Be Effectively Salvaged with Intensive Chemotherapy Followed by Cellular Therapy." @default.
• W2580025711 doi "https://doi.org/10.1182/blood.v114.22.2265.2265" @default.
• W2580025711 hasPublicationYear "2009" @default.
• W2580025711 type Work @default.
• W2580025711 sameAs 2580025711 @default.
• W2580025711 citedByCount "0" @default.
• W2580025711 crossrefType "journal-article" @default.
• W2580025711 hasAuthorship W2580025711A5001573915 @default.
• W2580025711 hasAuthorship W2580025711A5011143459 @default.
• W2580025711 hasAuthorship W2580025711A5026724408 @default.
• W2580025711 hasAuthorship W2580025711A5032585809 @default.
• W2580025711 hasAuthorship W2580025711A5045018770 @default.
• W2580025711 hasAuthorship W2580025711A5051478948 @default.
• W2580025711 hasAuthorship W2580025711A5055334016 @default.
• W2580025711 hasAuthorship W2580025711A5072940837 @default.
• W2580025711 hasAuthorship W2580025711A5080466962 @default.
• W2580025711 hasAuthorship W2580025711A5081252933 @default.
• W2580025711 hasConcept C126322002 @default.
• W2580025711 hasConcept C141071460 @default.
• W2580025711 hasConcept C143998085 @default.
• W2580025711 hasConcept C144301174 @default.
• W2580025711 hasConcept C2776694085 @default.
• W2580025711 hasConcept C2776755627 @default.
• W2580025711 hasConcept C2777408962 @default.
• W2580025711 hasConcept C2779263901 @default.
• W2580025711 hasConcept C2780007613 @default.
• W2580025711 hasConcept C2780817109 @default.
• W2580025711 hasConcept C2911091166 @default.
• W2580025711 hasConcept C38180746 @default.
• W2580025711 hasConcept C71924100 @default.
• W2580025711 hasConceptScore W2580025711C126322002 @default.
• W2580025711 hasConceptScore W2580025711C141071460 @default.
• W2580025711 hasConceptScore W2580025711C143998085 @default.
• W2580025711 hasConceptScore W2580025711C144301174 @default.
• W2580025711 hasConceptScore W2580025711C2776694085 @default.
• W2580025711 hasConceptScore W2580025711C2776755627 @default.
• W2580025711 hasConceptScore W2580025711C2777408962 @default.
• W2580025711 hasConceptScore W2580025711C2779263901 @default.
• W2580025711 hasConceptScore W2580025711C2780007613 @default.
• W2580025711 hasConceptScore W2580025711C2780817109 @default.
• W2580025711 hasConceptScore W2580025711C2911091166 @default.
• W2580025711 hasConceptScore W2580025711C38180746 @default.
• W2580025711 hasConceptScore W2580025711C71924100 @default.
• W2580025711 hasLocation W25800257111 @default.
• W2580025711 hasOpenAccess W2580025711 @default.
• W2580025711 hasPrimaryLocation W25800257111 @default.
• W2580025711 hasRelatedWork W2086551264 @default.
• W2580025711 hasRelatedWork W2132067734 @default.
• W2580025711 hasRelatedWork W2341077074 @default.
• W2580025711 hasRelatedWork W2574387044 @default.
• W2580025711 hasRelatedWork W2578013095 @default.
• W2580025711 hasRelatedWork W2578657405 @default.
• W2580025711 hasRelatedWork W2584566446 @default.
• W2580025711 hasRelatedWork W2594150909 @default.
• W2580025711 hasRelatedWork W2600857345 @default.
• W2580025711 hasRelatedWork W2646049475 @default.
• W2580025711 hasRelatedWork W2792674246 @default.
• W2580025711 hasRelatedWork W2913125470 @default.
• W2580025711 hasRelatedWork W2923556687 @default.
• W2580025711 hasRelatedWork W2980259368 @default.
• W2580025711 hasRelatedWork W2981881350 @default.
• W2580025711 hasRelatedWork W3042191907 @default.
• W2580025711 hasRelatedWork W3087219843 @default.
• W2580025711 hasRelatedWork W3111233081 @default.
• W2580025711 hasRelatedWork W3183571373 @default.
• W2580025711 hasRelatedWork W3186850363 @default.
• W2580025711 isParatext "false" @default.
• W2580025711 isRetracted "false" @default.
• W2580025711 magId "2580025711" @default.
• W2580025711 workType "article" @default.